Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.63 |
| ▸ | HTR6 | P50406 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | UBE2N | P61088 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 2/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.51 |
| ▸ | HTR1B | P28222 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29375465 | 1.00 | HTR7 (0.63) | HTR7HTR6TSHRADORA2BSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2290149 | 0.99 | HTR7 (0.65) | HTR7HTR6TSHRADORA2BSMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL12804036 | 0.99 | HTR7 (0.62) | HTR7HTR6TSHRADORA2BSMN1; SMN2 | |
| SCHEMBL11152654 | 0.94 | HTR7 (0.73) | HTR7HTR6TSHRADORA2BSMN1; SMN2 | |
| SCHEMBL11152582 | 0.93 | HTR7 (0.74) | HTR7HTR6TSHRADORA2BSMN1; SMN2 | |
| SCHEMBL684356 | 0.91 | HTR7 (0.58) | HTR7HTR6TSHRADORA2BSMN1; SMN2 | |
| SCHEMBL2626922 | 0.89 | HTR7 (0.63) | HTR7HTR6TSHRADORA2BSMN1; SMN2 | |
| Citric Acid SCHEMBL3729558 | 0.89 | HTR7 (0.54) | HTR7HTR6TSHRADORA2BSMN1; SMN2 | |
| SCHEMBL4401766 | 0.88 | HTR7 (0.62) | HTR7HTR6TSHRADORA2BSMN1; SMN2 | |
| SCHEMBL4399057 | 0.88 | TSHR (0.72) | HTR7HTR6TSHRADORA2BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190046528-A1 | METHOD OF PREVENTING HAIR LOSS OR PROMOTING HAIR GROWTH BY USING PHOSPHODIESTERASE 3 INHIBITOR | SEOUL NATIONAL UNIVERSITY HOSPITAL (KR) | 2019-02-14 | — | — | US | claimed |
| CN-105012306-A | SAA derivative compounds in hypoxic state are capable of reducing eNOS and inhibiting oxidative stress induced diseases | JIANZHI BIOLOG TECHNOLOGY CO LTD | 2015-11-04 | — | — | CN | claimed |
| US-20150306107-A1 | SAA Derivative Compound Restores eNOS And Inhibits Oxidative Stress-Induced A Diseases In Hypoxia | JANSFAT BIOTECHNOLOGY CO., LTD. (TW) | 2015-10-29 | — | — | US | claimed |
| US-20150174157-A1 | INHALED NO DONOR PIPERAZINYL DERIVATIVE PREVENTING ALLERGIC PULMONARY VASCULAR AND BRONCHIAL INFLAMMATION BY REDUCING VEGF AND RESTORING eNOS IN HYPOXIC PULMONARY ARTERY | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2015-06-25 | — | — | US | claimed |
| CN-104274465-A | Use of DPA analogues for protecting physiological activity against dysfunction | CHEN ZHAOLIANG | 2015-01-14 | — | — | CN | claimed |
| US-8507506-B2 | Theophylline derivative inhibits osteoporosis | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2013-08-13 | — | — | US | claimed |
| US-20130095059-A1 | INHALED NO DONOR KMUPS DERIVATIVE PREVENTING ALLERGIC PULMONARY VASCULAR AND BRONCHIAL INFLAMMATION VIA SUPPRESSED CYTOKINES, INOS AND INFLAMMATORY CELL COUNTS IN ASTHMA MODEL | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2013-04-18 | — | — | US | claimed |
| US-20120184570-A1 | Theophylline Derivative Inhibits Osteoporosis | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2012-07-19 | — | — | US | claimed |
| US-20110124655-A1 | KMUP-1 CAPABLE OF TREATING HYPERTENSION | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2011-05-26 | — | — | US | claimed |
| US-20100317671-A1 | XANTHINE-BASED CYCLIC GMP-ENHANCING RHO-KINASE INHIBITOR INHIBITS PHYSIOLOGICAL ACTIVITIES OF LUNG EPITHELIAL CELL LINE | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2010-12-16 | — | — | US | claimed |
| US-20100022552-A1 | KMUP-1 CAPABLE OF TREATING HYPERTENSION | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2010-01-28 | — | — | US | claimed |
| US-20100016329-A1 | XANTHINE-BASED CYCLIC GMP-ENHANCING RHO-KINASE INHIBITOR INHIBITS PHYSIOLOGICAL ACTIVITIES OF LUNG EPITHELIAL CELL LINE | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2010-01-21 | — | — | US | claimed |
| US-20090306093-A1 | METHOD FOR TREATING PATIENT HAVING BENIGN PROSTATE HYPERPLASIA | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2009-12-10 | — | — | US | claimed |
| US-20090209560-A1 | ANTI-INFLAMMATION ACTIVITY OF NEWLY SYNTHESIZED XANTHINE DERIVATIVES KMUP-1 AND KMUP-3 | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2009-08-20 | — | — | US | claimed |
| US-20080312249-A1 | KMUP-1 CAPABLE OF TREATING HYPERTENSION | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2008-12-18 | — | — | US | claimed |
| US-20080081816-A1 | ANTI-INFLAMMATION ACTIVITY OF NEWLY SYNTHESIZED XANTHINE DERIVATIVES KMUP-1 AND KMUP-3 | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2008-04-03 | — | — | US | claimed |
| US-20050209243-A1 | Theophylline-based soluble guanylyl cyclase activators KMUP-1 analogues enhanced cyclic GMP and K+ channel activities on rabbit corpus cavernosum smooth muscle and intercavernous pressure activities | Chen, Ing-Jun | 2005-09-22 | — | — | US | claimed |
| US-20050181066-A1 | Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | US | claimed |
| EP-1501605-A1 | NOVEL USE OF GUANYLATE CYCLASE ACTIVATORS FOR THE TREATMENT OF RESPIRATORY INSUFFICIENCY | ALTANA Pharma AG (DE) | 2005-02-02 | — | — | EP | claimed |
| WO-2003090870-A1 | NOVEL USE OF GUANYLATE CYCLASE ACTIVATORS FOR THE TREATMENT OF RESPIRATORY INSUFFICIENCY | ALTANA PHARMA AG (DE) | 2003-11-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130095059-A1 | INHALED NO DONOR KMUPS DERIVATIVE PREVENTING ALLERGIC PULMONARY VASCULAR AND BRONCHIAL INFLAMMATION VIA SUPPRESSED CYTOKINES, INOS AND INFLAMMATORY CELL COUNTS IN ASTHMA MODEL | NOS1, NOS3, NOS2 | HTR7 1664/4885HTR6 1719/4885TSHR 2884/4885 |
| US-20150306107-A1 | SAA Derivative Compound Restores eNOS And Inhibits Oxidative Stress-Induced A Diseases In Hypoxia | SAAL1, HMOX1, HIF1AN | HTR7 3988/4885HTR6 1856/4885TSHR 4579/4885 |
| US-20100317671-A1 | XANTHINE-BASED CYCLIC GMP-ENHANCING RHO-KINASE INHIBITOR INHIBITS PHYSIOLOGICAL ACTIVITIES OF LUNG EPITHELIAL CELL LINE | RHOA, PRKG1, ROCK1 | HTR7 4144/4885HTR6 4464/4885TSHR 4819/4885 |
| US-20050209243-A1 | Theophylline-based soluble guanylyl cyclase activators KMUP-1 analogues enhanced cyclic GMP and K+ channel activities on rabbit corpus cavernosum smooth muscle and intercavernous pressure activities | PRKG1, PDE3A, GUCY1A1 | HTR7 2129/4885HTR6 1843/4885TSHR 4357/4885 |
| US-20120184570-A1 | Theophylline Derivative Inhibits Osteoporosis | THOP1, CCL5, TBXAS1 | HTR7 888/4885HTR6 695/4885TSHR 581/4885 |
| US-20150174157-A1 | INHALED NO DONOR PIPERAZINYL DERIVATIVE PREVENTING ALLERGIC PULMONARY VASCULAR AND BRONCHIAL INFLAMMATION BY REDUCING VEGF AND RESTORING eNOS IN HYPOXIC PULMONARY ARTERY | NOS2, NOS3, NOS1 | HTR7 3923/4885HTR6 4695/4885TSHR 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.